ライフサイエンスコーパス: gingival overgrowth

1 PTEN's role in the etiology of drug-induced gingival overgrowth.

2 ve a role in the pathogenesis of CsA-induced gingival overgrowth.

3 se and tensin homolog (PTEN) in drug-induced gingival overgrowth.

4 diseases, is overexpressed in the tissue of gingival overgrowth.

5 emory T cells play a key role in CsA-induced gingival overgrowth.

6 iting role of curcumin in the development of gingival overgrowth.

7 ens of eight adult patients with generalized gingival overgrowth.

8 characteristic of all drug-induced forms of gingival overgrowth.

9 nifedipine, and cyclosporine-A often causes gingival overgrowth.

10 hesis that EMT likely occurs in drug-induced gingival overgrowth.

11 CCN2/CTGF expression is elevated in fibrotic gingival overgrowth.

12 ltaneous decrease in apoptosis contribute to gingival overgrowth.

13 poptosis could contribute to the etiology of gingival overgrowth.

14 h are the main complications of drug-induced gingival overgrowth.

15 fibrogenic molecules in gingiva and promote gingival overgrowth.

16 itive effect of those drugs on the degree of gingival overgrowth.

17 e inhibitor and estradiol benzoate developed gingival overgrowth.

18 (HGF) is a rare, autosomal dominant form of gingival overgrowth.

19 trols, cyclosporin A-, or nifedipine-induced gingival overgrowth.

20 ent of fibrotic lesions in phenytoin-induced gingival overgrowth.

21 ted with CsA treatment is the development of gingival overgrowth.

22 tant role in the pathogenesis of CsA-induced gingival overgrowth.

23 requent side effect of CSA administration is gingival overgrowth.

24 rticularly in the oral cavity manifesting as gingival overgrowth.

25 ted with isradipine exhibited an increase in gingival overgrowth.

26 e extent, or prevalence of phenytoin-induced gingival overgrowth.

27 if any, between phenytoin or HPPH levels and gingival overgrowth.

28 ssessed for signs of periodontal disease and gingival overgrowth.

29 n in man, and the prevalence and severity of gingival overgrowth.

30 prevent or attenuate phenytoin-induced human gingival overgrowth, although specific human studies are

31 ues from 20 different individuals with human gingival overgrowth and 15 non-overgrowth samples were e

32 mouse model to mimic human phenytoin-induced gingival overgrowth and assess the ability of a drug to

33 th in mice mimics molecular aspects of human gingival overgrowth and that lovastatin normalizes the t

34 Two-year follow-up revealed that both the gingival overgrowth and the destructive lesions were suc

35 howed severe gingival inflammation with some gingival overgrowth and various degrees of periodontal a

36 patients and PHT-treated patients exhibiting gingival overgrowth as well as patients with severe ging

37 Gingival overgrowth associated with cyclosporin (immunos

38 nt of prevention or treatment modalities for gingival overgrowth based on blocking the fibrogenic act

39 The gingival overgrowth can be due to three causes: noninfla

40 ve demonstrated that other drugs which cause gingival overgrowth can upregulate macrophage PDGF-B gen

41 PHT-treated patients exhibiting gingival overgrowth demonstrated a significant increase

42 CSA-treated patients exhibiting gingival overgrowth demonstrated approximately 48-fold i

43 PHT-treated patients exhibiting gingival overgrowth demonstrated no significant increase

44 increased tissue volume such as drug-induced gingival overgrowth (DGO).

45 The extent of gingival overgrowth did not correlate significantly with

46 wed that apoptosis decreased in all forms of gingival overgrowth examined (p < 0.05), and inflammatio

47 The extent and severity of gingival overgrowth for 164 renal transplant recipients

48 Drug-induced gingival overgrowth (GO) is a frequent and adverse side-

49 and periodontal variables were collected and gingival overgrowth (GO) was assessed by visual examinat

50 arkers (OSMs) in cyclosporin A (CsA)-induced gingival overgrowth (GO).

51 pe cytokines in cyclosporine A (CsA)-induced gingival overgrowth (GO).

52 ing the molecular mechanisms of drug-induced gingival overgrowth have demonstrated that PHT alters th

53 ival overgrowth in children are drug-induced gingival overgrowth, hereditary gingival fibromatosis (H

54 ominent side effect of CSA administration is gingival overgrowth (hyperplasia).

55 The most prevalent types of gingival overgrowth in children are drug-induced gingiva

56 Data indicate that phenytoin-induced gingival overgrowth in mice mimics molecular aspects of

57 rmine whether the prevalence and severity of gingival overgrowth in renal transplant recipients conco

58 e TGF-beta1 gene influence the expression of gingival overgrowth in renal transplant recipients conco

59 an independent genetic determinant of severe gingival overgrowth in the susceptible subjects studied.

60 characterization of phenytoin-induced human gingival overgrowth in vivo and in vitro characteristics

61 re were significant correlations between the gingival overgrowth index and both the papillary bleedin

62 pth (r = 0.301; P < 0.005), but not with the gingival overgrowth index.

63 The prevalence of gingival overgrowth induced by amlodipine or diltiazem w

64 The prevalence of gingival overgrowth induced by chronic medication with c

65 Gingival overgrowth induced by drugs such as phenytoin,

66 Thus, estradiol alone prevented the onset of gingival overgrowth induced by estrogen suppression.

67 rat hyperplastic connective tissue and human gingival overgrowth induced by PHT treatment revealed th

68 Gingival overgrowth is a common side effect following th

69 Gingival overgrowth is a common side-effect of the admin

70 Drug-induced gingival overgrowth is a known side effect of certain ch

71 Drug-induced gingival overgrowth is a tissue-specific condition and i

72 Drug-induced gingival overgrowth is an iatrogenic disease caused by t

73 Drug-induced gingival overgrowth is caused by the antiseizure medicat

74 Gingival overgrowth is caused by the formation of plexif

75 Gingival overgrowth is the enlargement of the attached g

76 ecular and cellular characteristics of human gingival overgrowth lesions and highlight how they diffe

77 Characteristics of these drug-induced gingival overgrowth lesions differ.

78 Although ciclosporin-induced gingival overgrowth lesions exhibit principally the pres

79 hogenetic mechanisms underlying drug-induced gingival overgrowth may be enhanced secretion of IL-6 by

80 ular mechanisms responsible for drug-induced gingival overgrowth may involve upregulation of PDGF-B m

81 These findings elucidate the mechanisms for gingival overgrowth mediated by SOS1 gene mutation in hu

82 ical examination revealed moderate to severe gingival overgrowth on both mandible and maxilla.

83 rst report on direct and indirect effects of gingival overgrowth-related medications on GF IL-6 metab

84 s that epithelial plasticity and EMT promote gingival overgrowth, resulting in compromised basal memb

85 Gingival overgrowth samples were obtained from patients

86 odon 25 had a significantly higher (P= 0.04) gingival overgrowth score than those who were homozygous

87 l proliferation was elevated in all forms of gingival overgrowth tested, independent of inflammation

88 Based partly on the histopathology of gingival overgrowth, the present study investigates the

89 cision is the current treatment modality for gingival overgrowth, the recurrent rate is high despite

90 cantly (P<0.05) higher compared to the other gingival overgrowth tissues and the controls.

91 ly higher CTGF staining in phenytoin-induced gingival overgrowth tissues compared to controls, cyclos

92 Gingival overgrowth tissues have thickened connective ti

93 Disrupted basal membrane structure in gingival overgrowth tissues is accompanied by a disconti

94 Nifedipine- and cyclosporine A-induced gingival overgrowth tissues similarly contain diminished

95 Higher CTGF staining in phenytoin gingival overgrowth tissues was accompanied by an increa

96 and extracellular CTGF content in phenytoin gingival overgrowth tissues was significantly (P<0.05) h

97 We found that phenytoin-induced human gingival overgrowth tissues, the most fibrotic drug-indu

98 epithelial cells could be observed in human gingival overgrowth tissues.

99 that important EMT markers occur in clinical gingival overgrowth tissues.

100 tissue growth factor (CTGF) in drug-induced gingival overgrowth tissues.

101 atients receiving CSA therapy and exhibiting gingival overgrowth to determine if similar PDGF-B upreg

102 presented with an unusual maxillary anterior gingival overgrowth treated by excisional biopsy.

103 or codon 25 independent predictors of severe gingival overgrowth were the heterozygous arginine/proli